Exposure to Extremely Low Frequency Magnetic Fields Induces Fos-Related Antigen-Immunoreactivity Via Activation of Dopaminergic D1 Receptor.
- Author:
Eun Joo SHIN
1
;
Xuan Khanh NGUYEN
;
Thuy Ty NGUYEN
;
Diem Thu PHAM
;
Hyoung Chun KIM
Author Information
- Publication Type:Original Article
- Keywords: extremely low frequency magnetic fields; Fos-related antigen; locomotor activity; dopaminergic D1 receptor; striatal complex
- MeSH: Animals; Benzazepines; Magnetic Fields; Magnetics; Magnets; Mice; Motor Activity; Neurons; Nucleus Accumbens; Sulpiride; Transcription Factor AP-1; Transcription Factors
- From:Experimental Neurobiology 2011;20(3):130-136
- CountryRepublic of Korea
- Language:English
- Abstract: We previously demonstrated that repeated exposure to extremely low frequency magnetic fields (ELF-MF) increases locomotor activity via stimulation of dopaminergic D1 receptor (J. Pharmacol. Sci., 2007;105:367-371). Since it has been demonstrated that activator protein-1 (AP-1) transcription factors, especially 35-kDa fos-related antigen (FRA), play a key role in the neuronal and behavioral adaptation in response to various stimuli, we examined whether repeated ELF-MF exposure induces FRA-immunoreactivity (FRA-IR) in the striatum and nucleus accumbens (striatal complex) of the mice. Repeated exposure to ELF-MF (0.3 or 2.4 mT, 1 h/day, for consecutive fourteen days) significantly induced hyperlocomotor activity and FRA-IR in the striatal complex in a field intensity-dependent manner. ELF-MF-induced FRA-IR lasted for at least 1 year, while locomotor activity returned near control level 3 months after the final exposure to ELF-MF. Pretreatment with SCH23390, a dopaminergic D1 receptor antagonist, but not with sulpiride, a dopaminergic D2 receptor antagonist, significantly attenuated hyperlocomotor activity and FRA-IR induced by ELF-MF. Our results suggest that repeated exposure to ELF-MF leads to prolonged locomotor stimulation and long-term expression of FRA in the striatal complex of the mice via stimulation of dopaminergic D1 receptor.
